Code42 Delivers Three Consecutive Years of Triple-Digit Growth Across its Insider Risk Management Business

Code42 today announced it is beginning 2022 with continued strong momentum in its Insider Risk Management business, growing Annual Recurring Revenue more than 125% in 2021. Code42 is arming organizations with the tools and education they need to make a fundamental shift in the ways company data is protected from theft and loss in today’s collaborative and remote work environment – this focus will continue to drive Code42’s growth in 2022.

Read More

Mirantis on run rate over $100M two years after buying Docker Enterprise assets

When Docker announced it was selling Docker Enterprise in 2019, it was a big surprise to industry watchers. Perhaps an even bigger surprise was that the buyer was Mirantis, a company best known for commercializing the OpenStack project. After the sale, Docker pivoted to a developer-focused company and reported last week it had $50 million in ARR last year.

Read More® Extends Previously Announced $180M Financing with Additional $31.5M Investment from Hildred Capital

NEW YORK & MIAMI–(BUSINESS WIRE)–, a leading data-driven insurtech platform, announced today the extension of its recent Series C equity round, which was led by Oaktree Capital Management, L.P. (“Oaktree”) as well as existing investors AXIS Capital, Second Alpha and Link Ventures. The additional $31.5M in Series C equity financing came from healthcare-focused private equity firm Hildred Capital Management (“Hildred”), bringing the total funding round to $211.5M.

Read More

Prove Ranked as Identity Verification Leader by G2 Users

“We are humbled to be acknowledged as a top leader by G2, a ranking from customers and users of our product, showcasing the value and power of Prove’s platform, innovation, and commitment as a leader in the digital identity space,” said Rodger Desai, Co-Founder and CEO of Prove. “Prove is on a mission to deliver digital trust, allowing businesses to garner the confidence to do more in the digital-first world that continues to evolve.

Read More

23andMe gets FDA clearance for prostate cancer risk test

Genetics testing company 23andMe received Food and Drug Administration clearance for its prostate cancer risk test, the company announced today. It’s 23andMe’s third clearance for a cancer risk report — the company also has tests for genes that predict breast and colorectal cancer risk.

Read More

UserTesting Announces Pricing Of Initial Public Offering

UserTesting, Inc. (“UserTesting”), a leading provider of human insight, delivered through a video-first, experience testing platform, today announced the pricing of its initial public offering of 10,000,000 shares of common stock at a public offering price of $14.00 per share.

Read More

23andMe Agrees to Acquire Lemonaid Health

23andMe Holding Co. (Nasdaq: ME) (“23andMe”), a leading consumer genetics and research company, today announced the signing of a definitive merger agreement with Lemonaid Health, Inc., an on-demand platform for accessing medical care and pharmacy services online.

Read More

UserTesting Files Registration Statement for Proposed Initial Public Offering

UserTesting, Inc. (“UserTesting”), a leading provider of human insight, delivered through a video-first, enterprise SaaS platform, today announced that it has publicly filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission (“SEC”) relating to a proposed initial public offering of shares of its common stock.

Read More